IN2014KN01714A - - Google Patents
Info
- Publication number
- IN2014KN01714A IN2014KN01714A IN1714KON2014A IN2014KN01714A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A IN 1714KON2014 A IN1714KON2014 A IN 1714KON2014A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A
- Authority
- IN
- India
- Prior art keywords
- antibody
- cancer
- amino acid
- acid sequence
- seq
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102100029949 Caprin-1 Human genes 0.000 abstract 1
- 101710072528 Caprin-1 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012035342 | 2012-02-21 | ||
| PCT/JP2013/054312 WO2013125630A1 (ja) | 2012-02-21 | 2013-02-21 | 癌の治療及び／又は予防用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN01714A true IN2014KN01714A (Direct) | 2015-10-23 |
Family
ID=49005808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1714KON2014 IN2014KN01714A (Direct) | 2012-02-21 | 2013-02-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9260513B2 (Direct) |
| EP (1) | EP2818481B1 (Direct) |
| JP (1) | JP6187257B2 (Direct) |
| KR (1) | KR102005308B1 (Direct) |
| CN (1) | CN104114581B (Direct) |
| AU (1) | AU2013223137B2 (Direct) |
| BR (1) | BR112014021099A2 (Direct) |
| CA (1) | CA2864999C (Direct) |
| DK (1) | DK2818481T3 (Direct) |
| ES (1) | ES2749672T3 (Direct) |
| HU (1) | HUE046788T2 (Direct) |
| IN (1) | IN2014KN01714A (Direct) |
| MX (1) | MX363136B (Direct) |
| PL (1) | PL2818481T3 (Direct) |
| PT (1) | PT2818481T (Direct) |
| RU (1) | RU2639522C2 (Direct) |
| WO (1) | WO2013125630A1 (Direct) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2471379T3 (es) | 2008-08-05 | 2014-06-26 | Toray Industries, Inc. | Método para detectar el cáncer |
| BRPI0911926A2 (pt) | 2008-08-05 | 2020-08-18 | Toray Industries, Inc | composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo. |
| ES2540858T3 (es) * | 2010-02-04 | 2015-07-14 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención de cáncer |
| DK2740489T3 (en) * | 2011-08-04 | 2017-01-16 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
| PT2741085T (pt) * | 2011-08-04 | 2017-06-30 | Toray Industries | Método para a deteção de cancro prancreático |
| RU2631804C2 (ru) | 2012-02-21 | 2017-09-26 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения или профилактики рака |
| US9416193B2 (en) * | 2012-03-30 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| AU2013241043B2 (en) | 2012-03-30 | 2017-11-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gall bladder cancer |
| CN104471403B (zh) | 2012-07-19 | 2017-03-01 | 东丽株式会社 | 癌的检测方法 |
| MX358772B (es) | 2012-07-19 | 2018-09-04 | Toray Industries | Metodo para detectar cancer. |
| KR102255616B1 (ko) | 2013-08-09 | 2021-05-25 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| CA3041979A1 (en) | 2016-10-28 | 2018-05-03 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| KR20200136935A (ko) | 2018-03-30 | 2020-12-08 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CN114585390A (zh) | 2019-06-13 | 2022-06-03 | 博尔特生物治疗药物有限公司 | 氨基苯并氮呯化合物、免疫缀合物及其用途 |
| CN114746404A (zh) | 2019-09-30 | 2022-07-12 | 博尔特生物治疗药物有限公司 | 酰胺连接的氨基苯并氮杂䓬免疫缀合物及其用途 |
| MX2022004875A (es) | 2019-10-25 | 2022-06-17 | Bolt Biotherapeutics Inc | Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos. |
| CA3175137A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2021182570A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2021182571A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| JP7793985B2 (ja) | 2020-03-12 | 2026-01-06 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| US20230159635A1 (en) * | 2020-03-12 | 2023-05-25 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2021226440A1 (en) | 2020-05-08 | 2021-11-11 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| CA3186059A1 (en) | 2020-08-13 | 2022-02-17 | Romas Kudirka | Pyrazoloazepine immunoconjugates, and uses thereof |
| WO2022270523A1 (ja) | 2021-06-23 | 2022-12-29 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2022270524A1 (ja) | 2021-06-23 | 2022-12-29 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| KR20240041917A (ko) | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| US20250325663A1 (en) | 2021-07-27 | 2025-10-23 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| US20250066502A1 (en) | 2021-07-27 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2023033129A1 (Direct) | 2021-09-03 | 2023-03-09 | ||
| US20250000995A1 (en) | 2021-10-29 | 2025-01-02 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| WO2024005123A1 (ja) | 2022-06-30 | 2024-01-04 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CN119744176A (zh) | 2022-08-24 | 2025-04-01 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| JPWO2024043257A1 (Direct) | 2022-08-24 | 2024-02-29 | ||
| WO2024043252A1 (ja) | 2022-08-24 | 2024-02-29 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CN119768184A (zh) | 2022-08-30 | 2025-04-04 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| WO2024048541A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| EP4640235A1 (en) | 2022-12-23 | 2025-10-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4665404A1 (en) | 2023-02-14 | 2025-12-24 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2025058000A1 (ja) * | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び／又は診断用医薬組成物 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| ATE340590T1 (de) | 1994-07-13 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| EP2363484A3 (en) | 1998-04-03 | 2012-04-25 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| PL200772B1 (pl) | 1998-07-14 | 2009-02-27 | Corixa Corp | Izolowany polipeptyd, fuzja białkowa oraz ich zastosowanie, izolowany epitop komórki T, wektor ekspresyjny, komórka gospodarza, sposób stymulowania i/lub namnażania komórek T, izolowana populacja komórek T, kompozycja i jej zastosowanie oraz izolowane komórki T |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| HK1045332A1 (zh) | 1999-04-02 | 2002-11-22 | Corixa Corporation | 用於治療和診斷肺癌的化合物及其使用方法 |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| JP2003528587A (ja) | 1999-10-29 | 2003-09-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ２７個のヒト分泌タンパク質 |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| HUP0500345A2 (hu) | 2000-03-29 | 2005-07-28 | Corixa Corporation | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására |
| AU2002239422B2 (en) | 2000-11-30 | 2006-12-07 | E. R. Squibb & Sons, L.L.C. | Transgenic transchromosomal rodents for making human antibodies |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| AU2002311909A1 (en) | 2001-05-11 | 2002-11-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| EP1970448A1 (en) | 2001-05-11 | 2008-09-17 | Kirin Pharma Kabushiki Kaisha | Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| JP2005535290A (ja) | 2002-02-22 | 2005-11-24 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| US20070048301A1 (en) | 2002-11-26 | 2007-03-01 | Bodary-Winter Sarah C | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| EP2361929A1 (en) | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
| PT1735348E (pt) | 2004-03-19 | 2012-07-24 | Imclone Llc | Anticorpo anti-receptor do factor de crescimento humano |
| PE20060287A1 (es) | 2004-03-30 | 2006-05-16 | Glaxo Group Ltd | INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| NZ556095A (en) | 2005-01-21 | 2010-01-29 | Genentech Inc | Fixed dosing of her antibodies |
| EP1849002A4 (en) | 2005-02-18 | 2008-08-20 | Childrens Medical Center | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| JP5069214B2 (ja) | 2005-03-11 | 2012-11-07 | ヴァーミリオン インコーポレイテッド | 卵巣癌及び子宮内膜癌のバイオマーカー：ヘプシジン |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| EP1991701A4 (en) | 2006-02-14 | 2010-03-17 | Dana Farber Cancer Inst Inc | COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER |
| WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2008031041A2 (en) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| KR101751065B1 (ko) | 2008-03-18 | 2017-06-26 | 제넨테크, 인크. | 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법 |
| PT2837383T (pt) | 2008-08-05 | 2017-03-17 | Toray Industries | Agente de indução de imunidade |
| ES2471379T3 (es) | 2008-08-05 | 2014-06-26 | Toray Industries, Inc. | Método para detectar el cáncer |
| BRPI0911926A2 (pt) * | 2008-08-05 | 2020-08-18 | Toray Industries, Inc | composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo. |
| EP2467401B1 (en) | 2009-08-19 | 2017-01-18 | Merck Patent GmbH | Antibodies for the detection of integrin complexes in ffpe material |
| JP5746183B2 (ja) | 2009-09-22 | 2015-07-08 | プロビオゲン アーゲー | 特定のグリカン構造を含有する分子を生成する方法 |
| RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
| US8709418B2 (en) | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
| EP2532366B1 (en) | 2010-02-04 | 2016-09-07 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| DK2532365T3 (en) | 2010-02-04 | 2016-08-15 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER |
| ES2540858T3 (es) | 2010-02-04 | 2015-07-14 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención de cáncer |
| RU2624029C2 (ru) * | 2010-02-04 | 2017-06-30 | Торэй Индастриз, Инк. | Лекарственный препарат для лечения и/или профилактики рака |
| ES2583777T3 (es) | 2010-02-04 | 2016-09-22 | Toray Industries, Inc. | Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer |
| KR101271964B1 (ko) | 2010-07-08 | 2013-06-07 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
| PL2598531T3 (pl) | 2010-07-26 | 2021-08-30 | Progastrine Et Cancers S.À R.L. | Sposoby i kompozycje do terapii nowotworu wątroby |
| JP5545105B2 (ja) | 2010-08-04 | 2014-07-09 | 株式会社ジェイテクト | トロイダル型無段変速機のディスクの研磨方法およびトロイダル無段変速機のディスクの研磨装置 |
| DK2740489T3 (en) | 2011-08-04 | 2017-01-16 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
| PT2741085T (pt) | 2011-08-04 | 2017-06-30 | Toray Industries | Método para a deteção de cancro prancreático |
| PT2740796T (pt) | 2011-08-04 | 2017-07-26 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| US9416193B2 (en) | 2012-03-30 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| AU2013241043B2 (en) | 2012-03-30 | 2017-11-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gall bladder cancer |
-
2013
- 2013-02-21 KR KR1020147020831A patent/KR102005308B1/ko active Active
- 2013-02-21 EP EP13751159.8A patent/EP2818481B1/en active Active
- 2013-02-21 ES ES13751159T patent/ES2749672T3/es active Active
- 2013-02-21 BR BR112014021099-3A patent/BR112014021099A2/pt not_active Application Discontinuation
- 2013-02-21 WO PCT/JP2013/054312 patent/WO2013125630A1/ja not_active Ceased
- 2013-02-21 DK DK13751159.8T patent/DK2818481T3/da active
- 2013-02-21 PL PL13751159T patent/PL2818481T3/pl unknown
- 2013-02-21 CN CN201380009166.3A patent/CN104114581B/zh active Active
- 2013-02-21 JP JP2013512279A patent/JP6187257B2/ja active Active
- 2013-02-21 HU HUE13751159A patent/HUE046788T2/hu unknown
- 2013-02-21 IN IN1714KON2014 patent/IN2014KN01714A/en unknown
- 2013-02-21 RU RU2014138039A patent/RU2639522C2/ru active
- 2013-02-21 MX MX2014009747A patent/MX363136B/es unknown
- 2013-02-21 PT PT137511598T patent/PT2818481T/pt unknown
- 2013-02-21 AU AU2013223137A patent/AU2013223137B2/en active Active
- 2013-02-21 US US14/379,868 patent/US9260513B2/en active Active
- 2013-02-21 CA CA2864999A patent/CA2864999C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2013125630A1 (ja) | 2015-07-30 |
| US20150044221A1 (en) | 2015-02-12 |
| CA2864999A1 (en) | 2013-08-29 |
| BR112014021099A2 (pt) | 2020-12-01 |
| HUE046788T2 (hu) | 2020-03-30 |
| ES2749672T3 (es) | 2020-03-23 |
| JP6187257B2 (ja) | 2017-08-30 |
| CA2864999C (en) | 2020-06-30 |
| WO2013125630A1 (ja) | 2013-08-29 |
| RU2639522C2 (ru) | 2017-12-21 |
| CN104114581A (zh) | 2014-10-22 |
| CN104114581B (zh) | 2018-11-30 |
| EP2818481A1 (en) | 2014-12-31 |
| AU2013223137A1 (en) | 2014-09-11 |
| EP2818481A4 (en) | 2015-10-07 |
| MX363136B (es) | 2019-03-12 |
| DK2818481T3 (da) | 2019-10-14 |
| PT2818481T (pt) | 2019-10-25 |
| KR102005308B1 (ko) | 2019-07-30 |
| US9260513B2 (en) | 2016-02-16 |
| KR20140130670A (ko) | 2014-11-11 |
| MX2014009747A (es) | 2014-11-14 |
| EP2818481B1 (en) | 2019-08-07 |
| RU2014138039A (ru) | 2016-04-10 |
| AU2013223137B2 (en) | 2017-10-19 |
| PL2818481T3 (pl) | 2020-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN01713A (Direct) | ||
| IN2014KN01714A (Direct) | ||
| IN2014KN01716A (Direct) | ||
| IN2014KN01715A (Direct) | ||
| MX2014001375A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX351414B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX358224B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado. | |
| MX360671B (es) | Composición farmacéutica para el tratamiento y/o prevención del cáncer. | |
| WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| NZ761006A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| NZ705370A (en) | Fcγriib-specific fc region variant | |
| MY167232A (en) | Polypeptides binding to human complement c5 | |
| IN2014DN09963A (Direct) | ||
| MX2016008989A (es) | Fragmentos mutantes de ospa y metodos y usos relacionados con estos. | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| GB201118201D0 (en) | Novel peptides | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. |